Targeted Treatment Slows Progression of Rare Connective Tissue Tumor

December 19, 2018

In a phase three clinical trial, a drug called sorafenib stopped progression of desmoid tumors for two years in 80 percent of patients who completed treatment, a significant increase in progression-free survival compared with placebo. (Progression-free survival is the length of time a patient lives without worsening of the disease.) 

Results of the multicenter trial were published in the New England Journal of Medicine.

 

Why it matters

There is no standard of care for patients with desmoid tumors. “In general, desmoids are locally aggressive and often painful tumors for which there are no effective therapies,” says Gary K. Schwartz, MD, chief of hematology/oncology at NewYork-Presbyterian/Columbia University Irving Medical Center and a senior author of the paper. “Sorafenib is an oral agent that provides a new means to directly target the ability of desmoid tumors to grow.” 

 

 

What are desmoid tumors?

Desmoid tumors (also called aggressive fibromatosis) are abnormal growths that arise in connective tissue and can occur anywhere in the body. Desmoid tumors are not considered cancerous, because they do not spread to other parts of the body. They do not often cause death, but these tumors can cause significant health problems by invading surrounding tissues, causing pain, limiting mobility, and interfering with organ function. About 1,000 new cases, mostly in young adults, are diagnosed in the United States each year.

Desmoid tumors are very complex and display a wide range of behaviors, even in the same patient. Some tumors shrink spontaneously, some remain stable, while still others grow aggressively. Treatment varies from patient to patient. In the past, most patients were treated with surgery, but because there is a high risk that the tumor will return, surgery is now mainly used for tumors that are thought to have a low risk of recurrence. Radiation, chemotherapy, and hormonal treatments are sometimes effective in reducing tumor size and alleviating pain.

 

What did the study do?

In this randomized, double-blinded trial, 87 patients with progressive, symptomatic, or recurrent desmoid tumors were given either oral sorafenib or placebo until scans showed disease progression.

Sorafenib is a targeted therapy that acts on tyrosine kinases—enzymes that have been implicated in cancer development—to inhibit the growth of cancer cells and the formation of new blood vessels that support tumor development. The drug has been approved by the FDA to treat certain types of advanced kidney, liver, and thyroid cancer. It has not yet been approved for the treatment of desmoid tumors.

 

What did the study find?

The study is ongoing, but the researchers estimate that progression-free survival after two years is 81 percent in those taking sorafenib and only 36 percent in those taking placebo. “This is a truly remarkable outcome,” says Schwartz, who is also a professor of oncology at Columbia University Vagelos College of Physicians and Surgeons.  “In fact, we have never seen results like this in the treatment of desmoid tumors.”

Side effects, including rash, hypertension, and diarrhea, were more common in patients taking sorafenib than in those taking placebo. 

 

Caveats

The study was designed to measure sorafenib’s effect on progression-free survival. It did not address whether the drug led to meaningful improvements in pain or other symptoms. 

In addition, 22 percent of patients in the treatment group discontinued therapy due to adverse events, such as fatigue and rash. 

 

What’s next 

Additional clinical trials are needed to identify the optimal dosage to reduce the risk of treatment-related adverse events and determine whether an increase in progression-free survival also leads to improvements in pain relief, function, and quality of life. 

Researchers are currently analyzing tumor samples obtained in this trial to better understand how sorafenib affects desmoid tumors at the molecular and cellular levels. Understanding sorafenib’s mechanism of action could lead to the development of additional therapies in the future. 

Topics

References

More Details

The study is titled “Sorafenib in Advanced and Refractory Desmoid Tumors.”

The other authors are Mrinal M. Gounder (Memorial Sloan Kettering Cancer Center), Michelle R. Mahoney (Mayo Clinic), Brian Andrew Van Tine (Washington University St. Louis), Vinod Ravi (MD Anderson), Steven Attia (Mayo Clinic), Hari Anant Deshpande (Yale), Abha A. Gupta (University Health Network Princess Margaret Cancer Center), Mohammed M. Milhem (University of Iowa), Robert Martin Conry (University of Alabama), Sujana Movva (Fox Chase Cancer Center), Michael J. Pishvaian (MedStar Georgetown University Hospital), Richard Riedel (Duke), Tarek Sabagh (Dayton NCI Community Oncology Research Program), William D. Tap (MSKCC), Natally Horvat (MSKCC), Ethan Basch (University of North Carolina), Lawrence Schwartz (Columbia University), Robert G. Maki (Northwell Cancer Institute), Narasimhan P. Agaram (MSKCC), Robert A. Lefkowitz (MSKCC), Yousef Mazaheri (MSKCC), Rikiya Yamashita (MSKCC), John Joseph Wright (National Cancer Institute), and Amylou C. Dueck (Mayo Clinic).

The study was supported by grants from the National Cancer Institute of the National Institutes of Health (U10CA180821U10CA180882, and U24CA196171U10CA180833U10CA180838U10CA180857U10CA180858UG1CA189850UG1CA189957U10CA180820U10CA180868U10CA180888, and U10CA180826), Bayer Pharmaceuticals, Memorial Sloan Kettering Cancer Center, American Society of Clinical Oncology, Desmoid Tumor Research Foundation, and Food and Drug Administration Orphan Products Clinical Trials Grants Program.

Dr. Schwartz receives consulting fees from Bayer Health Care Pharmaceuticals. Additional disclosures may be found in the paper.